Вы заканчиваете чтение этой книги. Сам факт, что вы её прочитали, ещё не решил ваши проблемы, но теперь вы знаете тайну здоровья. Не важно, какие болезни вас сейчас одолевают, вы можете вернуть себе здоровье, если будете настойчиво следовать инсулинопонижающему методу. Человеческое тело создано быть здоровым, и здоровое долголетие доступно каждому из вас. В ваших и только ваших силах изменить ситуацию к лучшему. Ни лекарства, ни врачи не смогут произвести в вашем теле нужные изменения – это можете сделать только вы сами! Используйте образное воображение! Попросите себе здоровья, представьте себя здоровыми – и вы ими станете!
Болезни у каждого разные. Просто вы заблудились на многочисленных тропинках, ведущим к болезням. Инсулинопонижающий метод (ИПМ) поможет вам выйти на единственно правильный широкий путь к здоровью. Сформулируйте свою конкретную цель, например, похудеть на 10 килограммов за полгода, или нормализовать давление за 3 месяца, или за 2 месяца снизить уровень сахара. Цель должна быть реальная и конкретная – такая, чтобы вы смогли её представить наяву. Начните соблюдать инструкции ИПМ, постепенно продвигаясь, если нужно, по схеме питания 3-2-1 и выполняя упражнения сначала со своим весом, а затем, по мере необходимости, с отягощениями.
Вас удивит быстрота нормализации тех параметров здоровья, которые вы наметили как цель. ИПМ – это универсальный метод оздоровления, поэтому попутно у вас улучшатся и другие показатели здоровья – самочувствие, работоспособность, настроение. Вы обретёте ощущение свободы тела и духа! Вы почувствуете – жизнь прекрасна!
Литература
Abraira, C., et al., 1999. Intensive insulin therapy in patients with type 2 diabetes: implications of the Veterans affairs (VA CSDM) feasibility trial. Am.Heart J. 138 (5 Pt 1), S360-S365.
Anson, R.M., et al., 2003. Intermittent fasting dissociates beneficial effects of dietary restriction on glucose metabolism and neuronal resistance to injury from calorie intake.Proc Natl Acad Sci U S A 2003 May 13;100(10):6216-20.
Benecke, H., et al., 1992. Alternatively spliced variants of the insulin receptor protein. Expression in normal and diabetic human tissues. J.Clin.Invest 89 (6), 2066-2070.
Bizzarri, C.,et al., 2006. Clinical effects of early treatment with insulin glargine in patients with cystic fibrosis and impaired glucose tolerance. J.Endocrinol.Invest 29 (3), RC1-RC4.
Bowker, S. L., et al., 2006. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin: Response to Farooki and Schneider. Diabetes Care 29 (8), 1990-1991.
Brahm, H., et al., 1997. Net fluxes over working thigh of hormones, growth factors and biomarkers of bone metabolism during short lasting dynamic exercise. Calcif Tissue Int. 1997 Feb;60(2):175-80.
Brelje, T. C., et al., 2004. Distinctive roles for prolactin and growth hormone in the activation of signal transducer and activator of transcription 5 in pancreatic islets of langerhans. Endocrinology 145 (9), 4162-4175.
Bucuvalas, J. C., et al., 2001. Effect of insulinlike growth factor-1 treatment in children with cystic fibrosis. J.Pediatr. Gastroenterol.Nutr. 33 (5), 576-581.
Burns, N., et al., 2007. Early-onset type 2 diabetes in obese white subjects is characterised by a marked defect in beta cell insulin secretion, severe insulin resistance and a lack of response to aerobic exercise training. Diabetologia. 2007 Mar 29.
Cauza, E., et al., 2005. The relative benefits of endurance and strength training on the metabolic factors and muscle function of people with type 2 diabetes mellitus. Arc Phys Med Reahabil. 2005 Aug;86(8):1527-33.
Castaneda, C., et al., 2002. A randomized controlled trial of resistance exercise training to improve glycemic control in older adults with type 2 diabetes. Diabetes Care. 2002 Dec;25(12):2335-41.
Clemmons, D. R., et al., 2005. Rh/IGF-I/rhIGFBP-3 administration to patients with type 2 diabetes mellitus reduces insulin requirements while also lowering fasting glucose. Growth Horm.IGF.Res. 15 (4), 265-274.
Cusi, K., et al., 2000. Recombinant human insulin-like growth factor I treatment for 1 week improves metabolic control in type 2 diabetes by ameliorating hepatic and muscle insulin resistance. J.Clin.Endocrinol.Metab 85 (9), 3077- 35 3084.
Cuttler L, Rosenfield RL. 2006. Somatic growth and maturation. In: DeGroot LJ, Jameson JL. Endocrinology Elsevier Inc., fifth ed., 697-701.
Den Ouden, D. T., et al., 2002. A 43-year-old male with untreated panhypopituitarism due to absence of the pituitary stalk: from dwarf to giant. J.Clin.Endocrinol.Metab 87 (12), 5430-5434.
Despres, J. P., et al., 1996. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N.Engl.J.Med. 334 (15), 952-9575.
Evans, J. M., et al., 2006. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 49 (5), 930-936.
Ewart, R. M., 2001. The case against aggressive treatment of type 2 diabetes: critique of the UK prospective diabetes study. BMJ 323 (7317), 854-858.
Fairey, A.S., et al., 2003. Effects of exercise training on fasting insulin, insulin resistance, insulin-like growth factors, and insulin-like growth factor binding proteins in postmenopausal breast cancer survivors: a randomized control trial. Cancer Epidemiol Biomarkers Prev. 2003 Aug;12(8):721-7.
Fasching, P., et al., 1994. Insulin production following intravenous glucose, arginine, and valine: different pattern in patients with impaired glucose tolerance and non-insulin-dependent diabetes mellitus. Metabolism 43 (3), 385-389.
Franco, C., et al., 2005. Growth hormone treatment reduces abdominal visceral fat in postmenopausal women with abdominal obesity: a 12-month placebo-controlled trial. J Clin Endocrinol Metab. 2005 Mar;90(3):1466-74.
Frasca, F., et al., 1999. Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol.Cell Biol. 19(5), 3278-3288.
Frasca, F., et al., 2008. The role of insulin receptors and IGF-I receptors in cancer and other diseases. Arch.Physiol Biochem. 114 (1), 23-37.
Froesch ER., et al., 1990. Insulin-Like Growth Factors. In: Ellenberg and Rifkin’s diabetes mellitus: theory and practice. 4th ed. Elsevier Science Publishing Co., Inc., NY; 154-169.
Geffner, M., et al., 2004. Changes in height, weight, and body mass index in children with craniopharyngioma after three years of growth hormone therapy: analysis of KIGS (Pfizer International Growth Database). J.Clin.Endocrinol.Metab 89 (11), 5435-5440.
Geffner, M. E., 1996. The growth without growth hormone syndrome. Endocrinol.Metab Clin.North Am. 25 (3), 649-663.
Goetz, F. C., et al., 1995. Are specific serum insulin levels low in impaired glucose tolerance and type II diabetes?: measurement with a radioimmunoassay blind to proinsulin, in the population of Wadena, Minnesota. Metabolism 44 (10), 1371-1376.
Goldspink, G., et al., 2002. Gene expression in response to muscle stretch. Clin Orthop Relat Res. 2002 Oct;(403 Suppl):S146-52.
Goldspink G. 1999. Changes in muscle mass and phenotype and the expression of autocrine and systemic growth factors by muscle in response to stretch and overload. J Anat. 1999 Apr;194 (Pt 3):323-34.
Gousseva, N., et al., 2001. Early growth response factor-1mediates insulin-inducible vascular endothelial cell proliferation and regrowth after injury. J.Cell Biochem 81 (3), 523-534.
Grunfeld, C., et al., 1980.Antibody-induced desensitization of the insulin receptor. Studies of the mechanism of desensitization in 3T3-L1 fatty fibroblasts. J Clin Invest. 66 (5), 1124-34.
Guler, H. P., et al., 1987. Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults. N.Engl.J.Med. 317 (3), 137-140.
Guler, H. P., et al., 1989. Effects of recombinant insulin like growth factor I on insulin secretion and renal function in normal human subjects. Proc.Natl.Acad.Sci.U.S.A 86 (8), 2868-2872.
Halberg, N., et al., 2005. Effect of intermittent fasting and refeeding on insulin action in healthy men. J Appl Physiol. 2005 Dec;99(6):2128-36.
Hanaire-Broutin, H., et al., 2000. Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens using insulin lispro in type 1 diabetic patients on intensified treatment: a randomized study. The Study Group for the Development of Pump Therapy in Diabetes. Diabetes Care, Vol 23, Issue 9 1232-1235
Hawkins M, Rosetti L. 2005. Insulin resistance and its role in the pathogenesis of type 2 diabetes. In: Kahn CR, et al. Joslin’s diabetes mellitus. 14th ed. Boston. 428.
Heidenreich, K. A., et al., 1988. Functional properties of the subtype of insulin receptor found on neurons. J.Neurochem. 51 (3), 878-887.
Heilbronn, L.K., et al., 2006. Effect of 6-month calorie restriction on biomarkers of longevity, metabolic adaptation, and oxidative stress in overweight individuals: a randomized controlled trial. JAMA. 2006 Apr 5;295(13):1539-48.
Hussain, K., et al., 2005. Hyperinsulinemic hypoglycemia in Beckwith-Wiedemann syndrome due to defects in the function of pancreatic beta-cell adenosine triphosphatesensitive potassium channels. J.Clin.Endocrinol.Metab 90(7), 4376-4382.
Ivovic, M., et al., 2006. [Insulin sensitivity in patients with adrenal incidentaloma]. Srp.Arh.Celok.Lek. 134 (7- 8), 315-3195.
Jee, S. H., et al., 2005. Fasting serum glucose level and cancer risk in Korean men and women. JAMA 293 (2), 194-202.
Jenab, M., et al., 2007. Serum C-peptide, IGFBP-1 and IGFBP-2 and risk of colon and rectal cancers in the European Prospective Investigation into Cancer and Nutrition. Int.J.Cancer 121 (2), 368-376.
Jensen, J., et al., 2005. STAT5 activation by human GH protects insulin-producing cells against interleukin-1beta, interferon-gamma and tumour necrosis factor-alphainduced apoptosis independent of nitric oxide production. J.Endocrinol. 187 (1), 25-36.
Jiang, Z. Y., et al., 1999. Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats. J.Clin.Invest 104 (4), 447- 457.
Johansson, G., et al., 1997. Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure. J Clin Endocrinol Metab. 1997 Mar;82(3):727-34.
Kahn CR, et al. In; Joslin’s diabetes mellitus. 14th ed. Boston. 2005; from pg. 111.
Katsuki, A., et al., 2003. Increased visceral fat and serum levels of triglyceride are associated with insulin resistance in Japanese metabolically obese, normal weight subjects with normal glucose tolerance. Diabetes Care 26(8), 2341-2344.
Katz, L. E., et al., 1999. Suppression of insulin oversecretion by subcutaneous recombinant human insulinlike growth factor I in children with congenital hyperinsulinism due to defective beta-cell sulfonylurea receptor. J.Clin.Endocrinol.Metab 84 (9), 3117-3124.
Kido, Y., et al., 2001. Clinical review 125: The insulin receptor and its cellular targets. J.Clin.Endocrinol.Metab 86 (3), 972-979.
Kimura, T., et al., 1999. Islet mass plays a critical role in initiation, but not progression, of the diabetogenic process in NOD mice. J.Autoimmun. 12 (4), 243-249.
Kitamura, T., et al., 2004. Mosaic analysis of insulin receptor function. J.Clin.Invest 113 (2), 209-2195.
Klein, R., et al., 1992. Epidemiology of proliferative diabetic retinopathy. Diabetes Care 15 (12), 1875-1891.
Kondo, T., et al., 2003. Knockout of insulin and IGF-1receptors on vascular endothelial cells protects against retinal neovascularization. J.Clin.Invest 111 (12), 1835-1842.
Kraemer, W.J., et al., 1999. Effects of heavy-resistance training on hormonal response patterns in younger vs. older men. J. Appl. Physiol. Sep;87(3)982-92.
Kulenovic, I., et al., 2004. Metabolic control and body mass index in patients with type 1 diabetes on different insulin regimens. Bosn.J.Basic Med.Sci. 4 (1), 23-28.
Kuzuya, H., et al., 1993. Trial of insulin-like growth factor I therapy for patients with extreme insulin resistance syndromes. Diabetes 42 (5), 696-705.
Larson-Meyer, D.E., 2006. Effect of calorie restriction with or without exercise on insulin sensitivity, beta-cell function, fat cell size, and ectopic lipid in overweight subjects. Diabetes Care 2006 Jun;29(6):1337-44
Leger, J., et al., 1997. Reduced final height and indications for insulin resistance in 20 year olds born small for gestational age: regional cohort study. BMJ 315 (7104), 341-347.
Li, L., et al., 2008. Immunotherapy of type 1 diabetes. Arch.Immunol.Ther.Exp.(Warsz.) 56 (4), 227-236.
Limburg, P. J., et al., 2006. Insulin, glucose, insulin resistance, and incident colorectal cancer in male smokers. Clin.Gastroenterol. Hepatol. 4 (12), 1514-1521.
Lukanova, A., et al., 2004. Prediagnostic levels of C-peptide, IGF-I, IGFBP -1, -2 and -3 and risk of endometrial cancer. Int.J.Cancer 108 (2), 262-268.
Lupi, R., et al., 2004.Improved insulin secretory function and reduced chemotactic properties after tissue culture of islets from type 1 diabetic patients.Diabetes Metab Res Rev. 20(3), 246-51.
Mattson, M.P., et al. 2005. Beneficial effects of intermittent fasting and caloric restriction on the cardiovascular and cerebrovascular systems. J Nutr Bochem. 2005 Mar;16(3):129-37.
Maedler, K., et al., 2001.Glucose induces beta-cell apoptosis via upregulation of the Fas receptor in human islets. Diabetes. 50(8),1683-90
Mannucci, E., et al., 2004. All-cause mortality in diabetic patients treated with combinations of sulfonylureas and biguanides. Diabetes Metab Res.Rev. 20 (1), 44-47.
McCormack, J., et al., 2000. Seeing what you want to see in randomised controlled trials: versions and perversions of UKPDS data. United Kingdom prospective diabetes study. 20 BMJ 320 (7251), 1720-1723.
McKoy, G., et al., 1999. Expression of insulin growth factor-1 splice variants and structural genes in rabbit skeletal muscle induced by stretch and stimulation. J Physiology.1999; 516.2, 583-592.
McCowern KC, Smith RJ. 2005. Insulin-like Growth Factors. In: Kahn CR, et al. Joslin’s diabetes mellitus. 14th ed. Boston. 2005; 169-178
Meier, J. J., et al., 2005. Pulsatile insulin secretion dictates systemic insulin delivery by regulating hepatic insulin extraction in humans. Diabetes 54 (6), 1649-1656.
Merimee, T. J., 1978. A follow-up study of vascular disease in growth-hormone-deficient dwarfs with diabetes. N.Engl.J.Med. 298 (22), 1217-1222.
Moller, D. E., et al 1989. Tissue-specific expression of two alternatively spliced insulin receptor mRNAs in man. Mol.Endocrinol. 3 (8), 1263-1269.
Moller, N., et al., 2003. Effects of growth hormone on lipid metabolism in humans. Growth Horm IGF Res. 2003 Aug;13 Suppl A:S18-21
Moses, A. C., et al., 1996. Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycemic control in type II diabetes. Diabetes 45 (1), 91-100.
Murashita, M., et al., 1999. Near-normal linear growth in the setting of markedly reduced growth hormone and IGF-1. A case report. Horm.Res. 51 (4), 184-188.
Murphy, L. J., 2006. Insulin-like growth factor-I: a treatment for type 2 diabetes revisited. Endocrinology 147 (6)5, 2616-2618.
Nesto RW, Libby P. 2001. Diabetes Mellitus and the Cardiovascular System. In: Heart Disease. A textbook of cardiovascular medicine. W.B. Saunders Company.
Oelz, O., et al., 1970. Nonsuppressible insulin-like activity (NSILA) of human serum. V. Hypoglycaemia and preferential metabolic stimulation of muscle by NSILA-S. Eur.J.Clin.Invest 1 (1), 48-53.
Olefsky JM, Molina JM. 1990. Insulin resistance in man. 121-129. In: Ellenberg and Rifkin’s diabetes mellitus: theory and practice. 4th ed. Elsevier Science Publishing Co., Inc., NY
Parkhouse, W. S., et al., 2000. IGF-1 bioavailability is increased by resistance training in older women with low bone mineral density. Mech. Ageing Dev. 2000. Feb 7;113(2):75-83.
Pickup JC, Williams G. Textbook of diabetes. 2nd ed. Blackwell Science Ltd, London. 1997.
Pischon, T., et al., 2006. Body size and risk of colon and rectal cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC). J.Natl.Cancer Inst. 98(13), 920-931.
Pollak, M., 2008. Insulin and insulin-like growth factor signalling in neoplasia. Nat.Rev.Cancer 8 (12), 915-928.
Porksen, N., et al., 1997. IGF-I inhibits burst mass of pulsatile insulin secretion at supraphysiological and low IGF-I infusion rates. Am.J.Physiol 272 (3 Pt 1), E352-E358.
Porksen, N., et al., 2002. Pulsatile insulin secretion: detection, regulation, and role in diabetes. Diabetes 51 Suppl 1S245-S254.
Porras, A., et al., 2003. Long-term treatment with insulin induces apoptosis in brown adipocytes: role of oxidative stress. Endocrinology 144 (12), 5390-5401.
Potau, N., et al., 1981. Insulin receptors in human placenta in relation to fetal weight and gestational age. Pediatr.Res. 15 (5), 798-802.
Puukka, R., et al., 1983. Erythrocyte insulin binding in normal infants, hildren and adults. Horm.Res. 17 (4),185-196.
Qian, H., et al., 2001. TNFalpha induces and insulin inhibits caspase 3-dependent adipocyte apoptosis. Biochem.Biophys.Res.Commun. 284 (5), 1176-1183.
Rao, S.S, et al., 2004. Impaired Glucose Tolerance and Impaired Fasting Glucose. American Family Phys, April 15.
Rasmussen, M.H., et al., 1995. Massive weight loss restores 24-hour growth hormone release profiles and serum insulin-like growth factor-I levels in obese subjects. J Clin Endocrinol Metab. 1995 Apr; 80(4):1407-15.
Reaven, G. M., et al., 1993. Plasma insulin, C-peptide, and proinsulin concentrations in obese and nonobese individuals with varying degrees of glucose tolerance. J.Clin.Endocrinol.Metab 76 (1), 44-48.
Rennert, N. J., et al., 1993. Insulin-like growth factor I inhibits glucose-stimulated insulin secretion but does not impair glucose metabolism in normal humans. J.Clin.Endocrinol.Metab 76 (3), 804-806.
Ripa, P., et al., 2002. The relationship between insulin secretion, the insulin-like growth factor axis and growth in children with cystic fibrosis. Clin.Endocrinol.(Oxf) 56 (3), 383-389.
Roth, G.S., 2001. Caloric restriction in primates and relevance to humans.Ann N Y Acad Sci.2001 Apr;928:305-15.
Ruderman, N., et al., 1998. The metabolically obese, normal weight individual revisited. Diabetes 47 (5), 699-713.
Sachdev, D., et al., 2006. Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: implications for anti-insulin-like growth factor therapy in breast cancer. Cancer Res. 66 (4), 2391-2402.
Salle, B. L., et al., 2001. [Intrauterine growth retardation, its consequences in infancy, in the child and long term]. 25 Bull.Acad.Natl.Med. 185 (7), 1271-1276.
Sekine, N., et al., 1998. GH signalling in pancreatic beta cells. Endocr.J. 45 SupplS33-S40.
Sesti, G., et al., 1995. Peptide-based radioimmunoassay for the two isoforms of the human insulin receptor. Diabetologia. 38(4),445-53.
Sesti, G., et al., 2001. Molecular mechanism of insulin resistance in type 2 diabetes mellitus: role of the insulin receptor variant forms. Diabetes Metab Res.Rev. 17 (5), 363-373.
Sesti, G., et al., 2001. Defects of the insulin receptor substrate (IRS) system in human metabolic disorders. FASEB J. 15 (12), 2099-2111.
Setia, S., et al., 2006. Insulin sensitivity and insulin secretion at birth in intrauterine growth retarded infants. Pathology 38 (3), 236-238.
Sherry, N. A., et al., 2006. Effects of autoimmunity and immune therapy on beta-cell turnover in type 1 diabetes. Diabetes. 55(12),3238-45.
Shimada, A., et al., 1996. Beta-cell destruction may be a late consequence of the autoimmune process in nonobese diabetic mice. Diabetes 45 (8),1063-1067.
Simpson, H. L., et al., 2004. Insulin-like growth factor I has a direct effect on glucose and protein metabolism, but no effect on lipid metabolism in type 1 diabetes. J.Clin.Endocrinol.Metab 89 (1), 425-432.
Simpson, S. H., et al., 2006. Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. CMAJ. 174 (2),169-174.
Singleton, J. R., et al., 2003. Microvascular complications of impaired glucose tolerance. Diabetes 52 (12), 2867-2873.
Soto, N., et al., 2003. Insulin sensitivity and secretion are related to catch-up growth in small-for-gestational-age infants at age 1 year: results from a prospective cohort. J.Clin.Endocrinol.Metab 88 (8), 3645-3650.
Stolzenberg-Solomon, R. Z., et al., 2005. Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers. JAMA 294 (22),2872-2878.
Swope, V. B., et al., 2001. Expression of insulin-like growth factor I by cultured skin substitutes does not replace the physiologic requirement for insulin in vitro. 30 J.Invest Dermatol. 116 (5), 650-657.
The Diabetes Control and Complications Trial Research Group. 1993. The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus. New Engl J Med. 1993 Sep; Vol 329: 977-986.
The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group. 2009. Modern-Day Clinical Course of Type 1 Diabetes Mellitus After 30 Years' Duration. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications and Pittsburgh Epidemiology of Diabetes Complications Experience (1983-2005). Arch Intern Med. 169(14):1307-1316.
Tran, T. T., et al., 2006. Hyperinsulinemia, but not other factors associated with insulin resistance, acutely enhances colorectal epithelial proliferation in vivo. Endocrinology 147 (4), 1830-1837.
Tulinius, H., et al., 1997. Risk factors for malignant diseases: a cohort study on a population of 22,946 Icelanders. Cancer Epidemiol.Biomarkers Prev. 6 (11), 863-873.
Van Assche, F. A., et al., 2001. Long-term consequences for offspring of diabetes during pregnancy. Br.Med.Bull. 60173-182.
Van Schravendijk, C. F., et al., 1990. Direct effect of insulin and insulin-like growth factor-I on the secretory activity of rat pancreatic beta cells. Diabetologia 33(11), 649-653.
Warram, J. H., et al., 1990. Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. Ann.Intern.Med. 113 (12), 909-915.
Warram JH, Krolewski AS. 2005. Epidemiology of diabetes mellitus. In: Kahn CR, et al. Joslin’s diabetes mellitus. 14th ed. Boston. 2005;341-45.
Weiss, e.p., et al. 2006. Improvements in glucose tolerance and insulin action induced by increasing energy expenditure or decreasing energy intake: a randomized controlled trial.Am J Clin Nutr. 2006. Nov;84(5):1033-42.
Wertheimer, E., et al., 2000. Differential roles of insulin receptor and insulin-like growth factor-1 receptor in differentiation of murine skin keratinocytes. J.Invest Dermatol. 115 (1), 24-29.
Wertheimer, E., et al., 2001. The regulation of skin proliferation and differentiation in the IR null mouse: implications for skin complications of diabetes. Endocrinology 142 (3), 1234-1241.
White, M. F., 1997. The insulin signalling system and the IRS proteins. Diabetologia 40 Suppl 2S2-17.
Xu, G., et al., 1998. Insulin mediates glucose-stimulated phosphorylation of PHAS-I by pancreatic beta cells. An insulin-receptor mechanism for autoregulation of protein synthesis by translation. J.Biol.Chem. 273 (8), 4485-4491.
Yin, D., et al., 2006. Recovery of islet beta-cell function in streptozotocin- induced diabetic mice: an indirect role for the spleen. Diabetes. 55(12),3256-63
Zapf, J., et al., 1981. Radioimmunological determination of insulinlike growth factors I and II in normal subjects and in patients with growth disorders and extrapancreatic tumor hypoglycemia. J.Clin.Invest 68 (5), 1321-1330.
Zapf, J., et al., 1986. Acute metabolic effects and half-lives of intravenously administered insulinlike growth factors I and II in normal and hypophysectomized rats. J.Clin.Invest 77 (6), 1768-1775.
Zenobi, P. D., et al., 1992. Insulin-like growth factor-I improves glucose and lipid metabolism in type 2 diabetes mellitus. J.Clin.Invest 90 (6), 2234-2241.
Zenobi, P. D., et al., 1992. Effects of insulin-like growth factor-I on glucose tolerance, insulin levels, and insulin secretion. J.Clin.Invest 89 (6),1908-1913.
Zhang, F., et al., 2006. Involvement of JAK2 and Src kinase tyrosine phosphorylation in human growth hormonestimulated increases in cytosolic free Ca2+ and insulin secretion. Am.J.Physiol Cell Physiol 291 (3).
Дополнительная литература к главам "О здоровом долголетии", "Работа мозга", "Простудные заболевания":
Anson RM., et al., 2003. Intermittent fasting dissociates beneficial effects of dietary restriction on glucose metabolism and neuronal resistance to injury from calorie intake. PNAS May 13, 2003 vol. 100 no. 10 6216-6220.
Hayflick L., 1982. Biological aspects of ageing. In: Proc Semin Biol and Soc Aspects Mortal and Length Life. Liege, p. 223-58.
Greene AE., et al., 2001. Caloric restriction inhibits seizure susceptibility in epileptic EL mice by reducing blood glucose. Epilepsia. Nov;42(11):1371-8.
Martin B., et al., 2006. Caloric restriction and intermittent fasting: two potential diets for successful brain aging. Ageing Res Rev. Aug;5(3):332-53.
Mattson MP., et al., 2003. Meal size and frequency affect neuronal plasticity and vulnerability to disease: cellular and molecular mechanisms. J Neurochem. Feb;84(3):417-31.
Mattson MP., et al., 2005. Beneficial effects of intermittent fasting and caloric restriction on the cardiovascular and cerebrovascular systems. J Nutr Biochem. Mar;16(3):129-37.
Venâncio TM., et al., 2003. A protein with amino acid sequence homology to bovine insulin is present in the legume Vigna unguiculata (cowpea). Braz J Med Biol Res. 2003 Sep;36(9):1167-73. Epub 2003 Aug 19.
LeRoith D. et al., 1985. Insulin-related material in microbes: similarities and differences from mammalian insulins. Can J Biochem Cell Biol;63(8):839-49.
Дополнительная литература к главе «Атеросклероз»:
Benditt EP. 1977. Implications of the monoclonal character of human atherosclerotic plaques. Am J Pathol. March; 86(3): 693–702.
Geng YJ, Libby P. 2002. Progression of atheroma: a struggle between death and procreation. Arterioscler Thromb Vasc Biol. Sep 1;22(9):1370-80.
Li J, Gao R. 2005. Should atherosclerosis be considered a cancer of the vascular wall? Medical Hypotheses, Volume 64, Issue 4, Pages 694-698.
Ross JS ., et al., 2001. Atherosclerosis: a cancer of the blood vessels? Am J Clin Pathol. Dec;116 Suppl:S97-107. Am J Clin Pathol. Dec;116 Suppl:S97-107.
Trosko JE, Chang CC. 1980. An integrative hypothesis linking cancer, diabetes and atherosclerosis: The role of mutations and epigenetic changes. Medical Hypotheses, Volume 6, Issue 5, Pages 455-468.
Paajanen T.A et al., 2010. Short stature is associated with coronary heart disease: a systematic review of the literature and a meta-analysis.Eur Heart J. 2010 Jun 8. [Epub ahead of print]
Tuomilehto J. 2010. Tall is beautiful and heart healthy?Eur Heart J. 2010 Jun 8. [Epub ahead of print]
Schulman S.P., et al., 2006. L-arginine therapy in acute myocardial infarction: the Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial.JAMA. Jan 4;295(1):58-64.
Дополнительная литература к главе "Повышенный вес и ожирение, или как похудеть".
Eaton SB., et al., 2009. Evolution, body composition, insulin receptor competition, and insulin resistance. Preventive Medicine 49 (2009) 283–285
Парадокс ожирения
Curtis J.P ., et al., 2005. The obesity paradox: body mass index and outcomes in patients with heart failure. Arch Intern Med. Jan 10;165(1):55-61.
Fonarow GC., et al., 2007. An obesity paradox in acute heart failure: analysis of body mass index and inhospital mortality for 108,927 patients in the Acute Decompensated Heart Failure National Registry. Am Heart J. Jan;153(1):74-81.
McAuley P ., et al., 2007. Body mass, fitness and survival in veteran patients: another obesity paradox? Am J Med. Jun;120(6):518-24.
Mullen J.T ., et al., 2009. The obesity paradox: body mass index and outcomes in patients undergoing nonbariatric general surgery. Ann Surg. Jul;250(1):166-72.